Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

Summary

The purpose of this study is to determine whether avelumab, an investigational antibody against programmed death-ligand (PD-L1), has an effect on recurrent nasopharyngeal cancer. Avelumab is designed to block the interaction between programmed cell death protein 1 (PD-1), a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer.

Timeline

Start

2017-01

Primary completion

2018-04

Completion

2019-04

Outcome

Outcome not reported

Stopped (Enrollment): “Slow patient accrual”

Drugs

Indications